Thread by @megtirrell

In written testimony posted ahead of Congressional hearing tomorrow, Moderna president Stephen Hoge notes the company is in the process of 'onboarding' another fill-finish partner (along w Catalent) for its #covid19 vaccine in the US: docs.house.gov/meetings/IF/IF…

Written testimony also showing how mRNA vaccine supply is ramping up in US:

Moderna says it aims to double output to 40M+ doses per month by April: docs.house.gov/meetings/IF/IF…

Pfizer says it's more than doubling to 13M+ doses per week by mid-March: docs.house.gov/meetings/IF/IF…

J&J updates on expected #covid19 vaccine supply in written congressional testimony for hearing tomorrow: 20M+ doses to US by end of March, assuming necessary regulatory approvals re: manufacturing (100M total by end of June; 1-dose vaccine): docs.house.gov/meetings/IF/IF…

AZ notes in congressional testimony that recruitment for its US ph3 #covid19 vaccine trial is now complete. Bc infection rate has been high, "we are hopeful that the readout of
the data will be available in the coming weeks." docs.house.gov/meetings/IF/IF…

AZ notes in testimony its US phase 3 #covid19 vaccine trial uses a 4-week interval for the doses, which "may not maximize efficacy" compared to a longer dosing schedule. (docs.house.gov/meetings/IF/IF…)

AZ says in testimony it's benefited from use of Defense Production Act: "Since the Defense Production Act Title I priority rating was put in place, our suppliers have not communicated any significant delays of materials or equipment." Doesn't specify dose # if/when granted EUA

AZ says it could take 8-9 months to update its #covid19 vaccine to new variants, which it's already working on for P1 (Brazil) and B.1.351 (South Africa): "it is likely the process from start to finished product would take 8 to 9 months to complete."

Novavax says in testimony it plans to begin clinical testing of new #covid19 vaccine candidates against variants in the first half of this year. With ph3 trial fully enrolled today, says it plans to complete FDA submission in Q2; supply: 110M doses by Q3: docs.house.gov/meetings/IF/IF…